drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Gene-modified T cells bearing a CD19-targeted chimeric antigen receptor and armored to secrete IL-7 and CCL19 to enhance proliferation, survival, and recruitment/trafficking of T cells and dendritic cells for treatment of CD19-positive B-cell lymphomas.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gene-modified T cells expressing a CD19-specific chimeric antigen receptor to recognize and kill CD19+ B cells via T-cell activation and cytotoxicity; additionally engineered to secrete IL-7 to enhance T-cell survival/proliferation and CCL19 to recruit/traffick T cells and dendritic cells to the tumor, improving infiltration and persistence.
drug_name
7x19 CAR-T (CD19 CAR T cells expressing IL-7 and CCL19)
nct_id_drug_ref
NCT06464861